Seres Therapeutics Inc (NASDAQ:MCRB) stock Posted Operating Margin of -84.92 percent in Last Year: Is Admissible?
Oppenheimer raised the price target for the Seres Therapeutics Inc (NASDAQ:MCRB) stock to “an Outperform”. The rating was released on June 26, 2023, according to finviz. The research report from Goldman has downgraded the stock from Neutral to Sell, with a price target set at $7. The stock was resumed by Goldman, who disclosed in […]
Seres Therapeutics Inc (MCRB) Stock creates opportunities due to its volume and complexity
Oppenheimer raised the price target for the Seres Therapeutics Inc (NASDAQ:MCRB) stock to “an Outperform”. The rating was released on June 26, 2023, according to finviz. The research report from Goldman has downgraded the stock from Neutral to Sell, with a price target set at $7. The stock was resumed by Goldman, who disclosed in […]
Seres Therapeutics Inc (NASDAQ:MCRB) stock Reported Profit Margin of -90.02 percent in Last Year: Is Defensible?
Oppenheimer raised the price target for the Seres Therapeutics Inc (NASDAQ:MCRB) stock to “an Outperform”. The rating was released on June 26, 2023, according to finviz. The research report from Goldman has downgraded the stock from Neutral to Sell, with a price target set at $7. The stock was resumed by Goldman, who disclosed in […]
Oppenheimer Assigned “an Outperform” Rating to Seres Therapeutics Inc (NASDAQ:MCRB) Stock
Oppenheimer raised the price target for the Seres Therapeutics Inc (NASDAQ:MCRB) stock to “an Outperform”. The rating was released on June 26, 2023, according to finviz. The research report from Goldman has downgraded the stock from Neutral to Sell, with a price target set at $7. The stock was resumed by Goldman, who disclosed in […]
Seres Therapeutics Inc (MCRB) Stock offers help to cash-strapped investors
Oppenheimer raised the price target for the Seres Therapeutics Inc (NASDAQ:MCRB) stock to “an Outperform”. The rating was released on June 26, 2023, according to finviz. The research report from Goldman has downgraded the stock from Neutral to Sell, with a price target set at $7. The stock was resumed by Goldman, who disclosed in […]
Seres Therapeutics Inc (NASDAQ:MCRB) stock Market Value Reached at $116.10 million: What Happened?
Oppenheimer raised the price target for the Seres Therapeutics Inc (NASDAQ:MCRB) stock to “an Outperform”. The rating was released on June 26, 2023, according to finviz. The research report from Goldman has downgraded the stock from Neutral to Sell, with a price target set at $7. The stock was resumed by Goldman, who disclosed in […]
Top-line Growth is Likely to Be Driven by Seres Therapeutics Inc (MCRB) Stock
Oppenheimer raised the price target for the Seres Therapeutics Inc (NASDAQ:MCRB) stock to “an Outperform”. The rating was released on June 26, 2023, according to finviz. The research report from Goldman has downgraded the stock from Neutral to Sell, with a price target set at $7. The stock was resumed by Goldman, who disclosed in […]
